Updates from a single-center phase 2 study of PD-1 inhibitor combined with hypomethylating agent plus CAG regimen in patients with relapsed/refractory acute myeloid leukemia - Zhou, Hui-Sheng; Su, Yong-Feng; Wang, Jun; Hu, Ya-Lei; Wang, An; Xu, Lei; Wang, Yi-Zhi; Zheng, Xuan; Li, Yu-Qing; Min, Kai-Li; Gao, Chun-Ji; Liu, Dai-Hong; et al. (Frontiers in Immunology, 2025)